Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment - sprookjes - yvandenbroek - TriplyDB

Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment

Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment

http://www.wikidata.org/entity/Q31037844

about

Vascular stem cells in diabetic complications: evidence for a role in the pathogenesis and the therapeutic promise Adipose-derived stem cells from diabetic mice show impaired vascular stabilization in a murine model of diabetic retinopathy.Glucose toxic effects on granulation tissue productive cells: the diabetics' impaired healing.Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy.MR angiography, MR imaging and proton MR spectroscopy in-vivo assessment of skeletal muscle ischemia in diabetic rats.Enhancement of neovascularization with mobilized blood cells transplantaion: supply of angioblasts and angiogenic cytokines.Obesity induced-insulin resistance causes endothelial dysfunction without reducing the vascular response to hindlimb ischemia.Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: roles of endothelial nitric oxide synthase and endothelial progenitor cells.Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies.Platelet released growth factors boost expansion of bone marrow derived CD34(+) and CD133(+) endothelial progenitor cells for autologous grafting.Molecular insights and therapeutic targets for diabetic endothelial dysfunction.Diabetic impairment of C-kit bone marrow stem cells involves the disorders of inflammatory factors, cell adhesion and extracellular matrix molecules Modulating Notch signaling to enhance neovascularization and reperfusion in diabetic mice.Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: treatment concept to correct diabetes-associated deficits.Beneficial effects of ginsenoside-Rg1 on ischemia-induced angiogenesis in diabetic mice.PPARγ activation but not PPARγ haplodeficiency affects proangiogenic potential of endothelial cells and bone marrow-derived progenitors.Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3.Diabetic Mesenchymal Stem Cells Are Ineffective for Improving Limb Ischemia Due to Their Impaired Angiogenic Capability.Blockade of NADPH oxidase restores vasoreparative function in diabetic CD34+ cells.PSGL-1-mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cells Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing.A novel autologous cell-based therapy to promote diabetic wound healing.Clinical and therapeutical implications of EPC biology in atherosclerosis.Vascular complications of diabetes: mechanisms of injury and protective factors Biology of bone marrow-derived endothelial cell precursors.Endothelial progenitor cells: a promising therapeutic alternative for cardiovascular disease.Promise of endothelial progenitor cell for treatment of diabetic retinopathy.Endothelial progenitor cells for the treatment of diabetic vasculopathy: panacea or Pandora's box?Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells.Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia.The promise of cell-based therapies for diabetic complications: challenges and solutions Endothelial progenitor cells and their potential therapeutic applications.Folic acid supplementation normalizes the endothelial progenitor cell transcriptome of patients with type 1 diabetes: a case-control pilot study.Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice.PPAR Gamma and Angiogenesis: Endothelial Cells Perspective.Bone marrow and pancreatic islets: an old story with new perspectives.Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes.Vascular dysfunction in diabetes: The endothelial progenitor cells as new therapeutic strategy.Towards the therapeutic use of vascular smooth muscle progenitor cells.Strategies to reverse endothelial progenitor cell dysfunction in diabetes

P2860

Q27026834-7A8D5199-1CAC-46D0-9900-C0DE8AD053C4 Q30300372-941E932C-AF08-4D70-B75A-3E4A4762634D Q30428132-5A6E9A2C-7C2F-4329-9532-05DCC4A90B14 Q30433579-AB3CA70E-9C40-4BFD-A90C-570DBB7C294B Q30571676-4CFC69CB-2FDE-40BA-ADF8-AA4BDA7B64BA Q33280223-8B032F49-EFCF-4E11-BFFA-1A08B089C9E8 Q33472763-22BC2AA9-0CEB-42DC-9B98-9B3E7A45C135 Q33553042-095529F8-DBD1-4F89-ADAB-19AA3251F1E0 Q33649275-9DC1E30E-17AC-4E53-86BE-FF1E6C5A8E40 Q33865124-A4DB6EFB-6295-4B17-81D8-45E32AB76017 Q34022332-C8837324-B532-4344-958D-C927572B5A7D Q34044884-1610F5AA-DE81-42AB-B14E-F470B31C1FEE Q34172388-6E98F242-F840-4E8C-A329-02FF51096F46 Q34433667-B89F12D5-EF93-42A0-84F3-BB91D91BD981 Q34461859-5457D60E-7B09-4CF5-85A1-9C9561741DE1 Q34518904-D66CED14-EB20-491B-8C14-4F73ED8D588B Q34849698-F3191167-2076-402A-BA9D-6C1B4433F24F Q35204126-1F53FC9C-4DDF-4E54-BBCA-32735B89CCA8 Q35221390-44A8831A-256D-4317-865A-A80958C34983 Q35785713-0ED8348C-30B6-4F57-8330-37DDA0C9152F Q35947546-319DF9E7-1FE0-48D1-BCF4-F12D731B6174 Q36301623-1F2599FB-D8D9-4C9A-9BF0-248EBB5B5CE0 Q36517055-6941D205-85D8-46F5-B0EF-02B061750EAF Q36537262-D4F3D0E4-7843-4DE6-8D27-2C22BD3FFEB5 Q36596218-CE5111BA-3406-4A2A-B19A-66F3A7CE826D Q36772905-B283CF43-59B2-411E-BC2A-4695DE8A8B98 Q36839005-C3AD7C65-0179-476D-AAB9-A38718048F2A Q36933858-C9D0A710-0CA6-4616-AAB0-8214719C0467 Q37101882-0BCD37E0-A037-46DD-B1C9-AA90AE25291F Q37131598-987B3A3A-7C18-4697-A74C-7099CD31D470 Q37276042-DDFA9AAB-7B95-4A59-9A19-239DA67BE2F1 Q37306806-CA74960B-7CE1-4D30-8856-69332A688DEC Q37337753-1A1D8AD6-EDB4-4F9C-AA6E-30E4CA666F96 Q37413615-F61308CB-CC38-4AB8-ACE7-39EC90C7B1DA Q37521530-D4F0C135-4A0F-4F56-B73A-B3C49F8423BD Q37780807-C019C7B9-BC50-49DD-A1C0-D8A763763967 Q37879983-7FC01442-41F7-4C83-951D-0BE8E332428B Q37921103-CBA6760A-F76A-4CA0-8181-582C7D401CA5 Q37987098-7F372542-6F5A-4E86-8C1E-B8B09E3E3945 Q37999783-C50A0CEA-1100-47C0-A2EB-D0052FEBA2CC

P2860

Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment

http://www.wikidata.org/entity/Q31037844

description

2004 nî lūn-bûn

@nan

2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Impairment in ischemia-induced ...... acenta growth factor treatment

@ast

Impairment in ischemia-induced ...... acenta growth factor treatment

@en

type

label

Impairment in ischemia-induced ...... acenta growth factor treatment

@ast

Impairment in ischemia-induced ...... acenta growth factor treatment

@en

prefLabel

Impairment in ischemia-induced ...... acenta growth factor treatment

@ast

Impairment in ischemia-induced ...... acenta growth factor treatment

@en

P1433

Q31037844-D304DDDC-E89B-45E9-A0F5-5431A9BF627E

P1476

Q31037844-8731F2FE-97CB-4333-AC95-31023D13C5B4

P2093

Q31037844-07DDB94E-D545-404B-BB63-CA6CF3A4F35C

Q31037844-310CA59B-5138-4EA1-ABD5-606D2B22664C

Q31037844-504AA1FD-7508-479F-AB0E-3ED3CE26B375

Q31037844-73B2F5EA-2407-4856-A01B-0F53B47BFFF9

Q31037844-7F42B8DD-15F5-479A-9F03-D9A07164467B

Q31037844-81FE72B5-8BF6-4A5C-94A8-5F16FAB69412

Q31037844-9E0F6839-0381-4935-B495-09B0E0C0BB0A

Q31037844-A5989C3A-EC5C-4C75-AED3-AC0F7A158C3A

Q31037844-CBFBD285-091C-4E2F-A875-95A300EC3BD7

P2860

Q31037844-2353D3F2-57F5-4CF2-9275-564425B99340

Q31037844-2FFA7CFE-0A77-46E4-A712-CA55CB99E542

Q31037844-540E9537-82A4-4952-BA44-5DBCA412D208

Q31037844-613B7FDA-9E28-41F6-86B1-BC7F5BA81458

Q31037844-67F00FA7-AD85-42BE-8262-314F8B5AE581

Q31037844-6977FBFE-DACB-490B-A668-D4D3FFB09488

Q31037844-6D50F8AB-6874-4ACA-A626-63E5AD141A9E

Q31037844-7A2EE227-5417-4B9B-ABC3-94821B95C441

Q31037844-B097AEC5-8923-4A24-913A-0566F7177023

Q31037844-BDC3CEDC-BCF6-4594-B1C2-19BB37FD3FA3

P304

Q31037844-DF99D6B4-6978-4E58-B4AE-436627A989A0

P31

Q31037844-264BBD10-C8EE-4016-A99A-19B97DB3EA37

P356

Q31037844-D3F8CEE3-66C7-42BC-ACD9-94C5A9A23F7A

P407

Q31037844-2F9F005C-2EAA-4503-AEA9-27C2BDFC8F20

P433

Q31037844-E1C35A92-DFCF-4300-BAD1-828B1E464B40

P478

Q31037844-22041CD6-3B91-4075-A285-E59DF4A32674

P577

Q31037844-76F52BC1-FE0F-4D38-BC21-A19DFB9CCE75

P698

Q31037844-A4C8712D-1B37-43AE-86CE-64FF9F31D0D3

P921

Q31037844-162C321D-929D-4C02-A392-A3BBBC300755

Q31037844-40085913-0510-404D-9230-123E08FEF986

P932

Q31037844-5B0F9F6D-81F8-4AB1-AAF0-D4CD8459AE93

P356

S0002-9440(10)63136-7

P1433

The American Journal of Pathology

P1476

Impairment in ischemia-induced ...... acenta growth factor treatment

@en

P2093

Bernard I Lévy

http://www.w3.org/2001/XMLSchema#string

Gérard Tobelem

http://www.w3.org/2001/XMLSchema#string

Jean-Sébastien Silvestre

http://www.w3.org/2001/XMLSchema#string

Laurence Lecomte-Raclet

http://www.w3.org/2001/XMLSchema#string

Michel Clergue

http://www.w3.org/2001/XMLSchema#string

Micheline Duriez

http://www.w3.org/2001/XMLSchema#string

Radia Tamarat

http://www.w3.org/2001/XMLSchema#string

Sophie Le Ricousse-Roussanne

http://www.w3.org/2001/XMLSchema#string

Véronique Barateau

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of angiogenesis and arteriogenesis

Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF.

Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis.

Interleukin-18/interleukin-18 binding protein signaling modulates ischemia-induced neovascularization in mice hindlimb.

Augmentation of postnatal neovascularization with autologous bone marrow transplantation.

Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.

Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function.

Endothelial dysfunction in diabetes.

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb.

P304

457-466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0002-9440(10)63136-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

164

http://www.w3.org/2001/XMLSchema#string

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14742252

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization

P932

1602274

http://www.w3.org/2001/XMLSchema#string